JP2019537600A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019537600A5 JP2019537600A5 JP2019523763A JP2019523763A JP2019537600A5 JP 2019537600 A5 JP2019537600 A5 JP 2019537600A5 JP 2019523763 A JP2019523763 A JP 2019523763A JP 2019523763 A JP2019523763 A JP 2019523763A JP 2019537600 A5 JP2019537600 A5 JP 2019537600A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- seq
- peg
- poly
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920000642 polymer Polymers 0.000 claims description 50
- 239000000203 mixture Substances 0.000 claims description 44
- 239000002105 nanoparticle Substances 0.000 claims description 43
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 26
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 24
- 150000001413 amino acids Chemical group 0.000 claims description 24
- 108020004707 nucleic acids Proteins 0.000 claims description 24
- 102000039446 nucleic acids Human genes 0.000 claims description 24
- 150000007523 nucleic acids Chemical class 0.000 claims description 24
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 22
- 229920001223 polyethylene glycol Polymers 0.000 claims description 22
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 125000002091 cationic group Chemical group 0.000 claims description 14
- 229920000359 diblock copolymer Polymers 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 229920003046 tetrablock copolymer Polymers 0.000 claims description 9
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 8
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 8
- 239000002246 antineoplastic agent Substances 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- -1 citalabine Chemical compound 0.000 claims description 8
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 108090000695 Cytokines Proteins 0.000 claims description 6
- 229920000724 poly(L-arginine) polymer Polymers 0.000 claims description 6
- 108010011110 polyarginine Proteins 0.000 claims description 6
- 241001455273 Tetrapoda Species 0.000 claims description 5
- 229920001400 block copolymer Polymers 0.000 claims description 5
- 229920001577 copolymer Polymers 0.000 claims description 5
- NMNDQBZTIMGTSF-UHFFFAOYSA-N 11h-indeno[1,2-h]isoquinoline Chemical compound C1=CN=CC2=C3CC4=CC=CC=C4C3=CC=C21 NMNDQBZTIMGTSF-UHFFFAOYSA-N 0.000 claims description 4
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims description 4
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 4
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 claims description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 4
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 claims description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 4
- 229930012538 Paclitaxel Natural products 0.000 claims description 4
- 229960004562 carboplatin Drugs 0.000 claims description 4
- 190000008236 carboplatin Chemical compound 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 229960000975 daunorubicin Drugs 0.000 claims description 4
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 4
- 229960003603 decitabine Drugs 0.000 claims description 4
- 229960003668 docetaxel Drugs 0.000 claims description 4
- 229960004679 doxorubicin Drugs 0.000 claims description 4
- 229960002949 fluorouracil Drugs 0.000 claims description 4
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 claims description 4
- 229960004768 irinotecan Drugs 0.000 claims description 4
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 4
- 229960000485 methotrexate Drugs 0.000 claims description 4
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 4
- 229960001756 oxaliplatin Drugs 0.000 claims description 4
- 229960001592 paclitaxel Drugs 0.000 claims description 4
- 229920001451 polypropylene glycol Polymers 0.000 claims description 4
- 229950007866 tanespimycin Drugs 0.000 claims description 4
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 claims description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 4
- 229940063683 taxotere Drugs 0.000 claims description 4
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 3
- 229960001467 bortezomib Drugs 0.000 claims description 3
- 108091023037 Aptamer Proteins 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 206010055114 Colon cancer metastatic Diseases 0.000 claims description 2
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- 208000012239 Developmental disease Diseases 0.000 claims description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
- 229920000463 Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) Polymers 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 230000021615 conjugation Effects 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 208000030172 endocrine system disease Diseases 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 208000028774 intestinal disease Diseases 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 208000030159 metabolic disease Diseases 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 229920000428 triblock copolymer Polymers 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 206010066476 Haematological malignancy Diseases 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022193548A JP2023014340A (ja) | 2016-11-02 | 2022-12-02 | ポリマーナノ粒子 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662416574P | 2016-11-02 | 2016-11-02 | |
| US62/416,574 | 2016-11-02 | ||
| PCT/US2017/059542 WO2018085407A1 (en) | 2016-11-02 | 2017-11-01 | Polymeric nanoparticles |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022193548A Division JP2023014340A (ja) | 2016-11-02 | 2022-12-02 | ポリマーナノ粒子 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019537600A JP2019537600A (ja) | 2019-12-26 |
| JP2019537600A5 true JP2019537600A5 (enExample) | 2020-11-12 |
Family
ID=62076348
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019523763A Pending JP2019537600A (ja) | 2016-11-02 | 2017-11-01 | ポリマーナノ粒子 |
| JP2022193548A Pending JP2023014340A (ja) | 2016-11-02 | 2022-12-02 | ポリマーナノ粒子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022193548A Pending JP2023014340A (ja) | 2016-11-02 | 2022-12-02 | ポリマーナノ粒子 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11484507B2 (enExample) |
| EP (1) | EP3534909A4 (enExample) |
| JP (2) | JP2019537600A (enExample) |
| KR (1) | KR20190082263A (enExample) |
| CN (1) | CN110114072A (enExample) |
| WO (1) | WO2018085407A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11345914B2 (en) * | 2017-07-11 | 2022-05-31 | Tokyo University Of Pharmacy And Life Sciences | Composition for delivering nucleic acid and nucleic acid-containing composition |
| CA3092338A1 (en) * | 2018-01-29 | 2019-08-01 | The Johns Hopkins University | Polymeric nanoparticle compositions for encapsulation and sustained release of protein therapeutics |
| CA3186633A1 (en) * | 2020-06-30 | 2022-01-06 | Hillstream Biopharma Inc. | Nanoparticles and methods of manufacture thereof |
| WO2022251844A1 (en) * | 2021-05-25 | 2022-12-01 | Hillstream Biopharma, Inc. | Polymeric nanoparticles comprising chemotherapeutic compounds and related methods |
| WO2023034605A1 (en) * | 2021-09-03 | 2023-03-09 | Hillstream Biopharma, Inc. | Polymeric nanoparticles comprising a histone deacetylase 6 / phosphoinositide 3-kinase-8 dual inhibitor and related methods |
| US12357645B2 (en) | 2023-03-09 | 2025-07-15 | Minneamrita Therapeutics Llc | Drug combination for treatment of gastric cancer |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7244823B2 (en) * | 2000-03-02 | 2007-07-17 | Xencor | TNF-alpha variants proteins for the treatment of TNF-alpha related disorders |
| JP2003525612A (ja) * | 2000-03-02 | 2003-09-02 | ゼンコー | ＴＮＦ−α関連障害の処置のための変種ＴＮＦ−αタンパク質の設計および発見 |
| FR2822156A1 (fr) | 2001-03-16 | 2002-09-20 | Centre Nat Rech Scient | Oligonucleotides pour la regulation du gene codant pour le tnf alpha et/ou de genes sous son controle et leurs applications |
| US20060165987A1 (en) | 2002-04-05 | 2006-07-27 | Patrice Hildgen | Stealthy polymeric biodegradable nanospheres and uses thereof |
| AU2005269800B8 (en) | 2004-07-19 | 2011-12-01 | Jazz Pharmaceuticals Therapeutics, Inc. | Particulate constructs for release of active agents |
| WO2007001448A2 (en) | 2004-11-04 | 2007-01-04 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
| JP6096398B2 (ja) | 2006-07-28 | 2017-03-15 | 株式会社ブリヂストン | 重合体ナノ粒子、ゴム組成物及び使用 |
| US20080081075A1 (en) | 2006-10-02 | 2008-04-03 | National Tsing Hua University | Multifunctional mixed micelle of graft and block copolymers and preparation thereof |
| JP2010523595A (ja) * | 2007-04-04 | 2010-07-15 | マサチューセッツ インスティテュート オブ テクノロジー | ポリ（アミノ酸）ターゲッティング部分 |
| WO2008139804A1 (ja) | 2007-05-14 | 2008-11-20 | Ltt Bio-Pharma Co., Ltd. | 徐放性の陰荷電基を持つ低分子薬物含有ナノ粒子 |
| JP2011500569A (ja) * | 2007-10-12 | 2011-01-06 | マサチューセッツ インスティテュート オブ テクノロジー | ワクチンナノテクノロジー |
| JP4824710B2 (ja) | 2008-02-08 | 2011-11-30 | 国立清華大学 | グラフト共重合体およびブロック共重合体の多機能混合ミセルならびにその製造方法 |
| EP2251006B1 (en) | 2008-02-22 | 2017-07-19 | Toray Industries, Inc. | Microparticles and pharmaceutical compositions thereof |
| US8591905B2 (en) * | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
| TWI541021B (zh) | 2009-03-05 | 2016-07-11 | 艾伯維有限公司 | Ｉｌ－１７結合蛋白 |
| CN102000340B (zh) | 2009-09-11 | 2012-10-31 | 江西科技师范学院 | 一种靶向性高分子药物载体及制备方法和应用 |
| US8952054B2 (en) | 2010-03-15 | 2015-02-10 | Dana-Farber Cancer Institute, Inc. | Small molecule inhibitors of MUC1 and methods of identifying the same |
| KR20130010123A (ko) | 2010-04-07 | 2013-01-25 | 아비에 인코포레이티드 | ＴＮＦ-α 결합 단백질 |
| JP5655147B2 (ja) | 2010-08-20 | 2015-01-14 | セルリアン・ファーマ・インコーポレイテッド | 治療用ペプチド−ポリマーの複合体、粒子、組成物および関連の方法 |
| AR084210A1 (es) | 2010-12-08 | 2013-05-02 | Abbott Lab | PROTEINAS DE UNION AL TNF-a |
| EP2714017B1 (en) * | 2011-06-02 | 2018-08-01 | The Regents of The University of California | Membrane encapsulated nanoparticles and method of use |
| EP2537933A1 (en) * | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
| CN102276813B (zh) | 2011-08-19 | 2013-01-16 | 江西科技师范学院 | 含叶酸靶向高分子药物载体及其制备方法 |
| PE20141545A1 (es) | 2011-10-24 | 2014-11-26 | Abbvie Inc | Inmunoenlazadores dirigidos contra el tnf |
| US9149426B2 (en) | 2012-02-15 | 2015-10-06 | University Of Tennessee Research Foundation | Nanoparticle composition and methods to make and use the same |
| CA2869748C (en) * | 2012-04-12 | 2017-10-24 | Yale University | Vehicles for controlled delivery of different pharmaceutical agents |
| EP2841486B1 (en) | 2012-04-23 | 2020-01-15 | NanoProteagen Ltd. | Polymeric nanoparticles and a process of preparation thereof |
| WO2014053882A1 (en) * | 2012-10-04 | 2014-04-10 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| EP2968510B1 (en) * | 2013-03-14 | 2019-10-09 | President and Fellows of Harvard College | Nanoparticle-based compositions |
-
2017
- 2017-11-01 CN CN201780080722.4A patent/CN110114072A/zh active Pending
- 2017-11-01 JP JP2019523763A patent/JP2019537600A/ja active Pending
- 2017-11-01 WO PCT/US2017/059542 patent/WO2018085407A1/en not_active Ceased
- 2017-11-01 KR KR1020197015816A patent/KR20190082263A/ko not_active Ceased
- 2017-11-01 EP EP17868431.2A patent/EP3534909A4/en active Pending
- 2017-11-01 US US16/466,566 patent/US11484507B2/en active Active
-
2022
- 2022-10-06 US US17/938,369 patent/US20230157969A1/en active Pending
- 2022-12-02 JP JP2022193548A patent/JP2023014340A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019537600A5 (enExample) | ||
| Musetti et al. | Nanoparticle-mediated remodeling of the tumor microenvironment to enhance immunotherapy | |
| Shi | Clinical translation of nanomedicine and biomaterials for cancer immunotherapy: progress and perspectives | |
| Wu et al. | Nanogel‐incorporated physical and chemical hybrid gels for highly effective chemo–protein combination therapy | |
| Noh et al. | Co-delivery of paclitaxel and gemcitabine via CD44-targeting nanocarriers as a prodrug with synergistic antitumor activity against human biliary cancer | |
| Doppalapudi et al. | Biodegradable polymers for targeted delivery of anti-cancer drugs | |
| JP2018536655A5 (enExample) | ||
| Yilmaz et al. | Polyphosphoesters: New trends in synthesis and drug delivery applications | |
| JP2012522055A5 (enExample) | ||
| Vandghanooni et al. | Recent advances in aptamer-armed multimodal theranostic nanosystems for imaging and targeted therapy of cancer | |
| Yu et al. | Synergy of immunostimulatory genetherapy with immune checkpoint blockade motivates immune response to eliminate cancer | |
| JP2012532185A5 (enExample) | ||
| L. Beretta et al. | Engineering nanomedicines to overcome multidrug resistance in cancer therapy | |
| JP2019521180A5 (enExample) | ||
| JP2013515745A5 (enExample) | ||
| Wang et al. | Engineering CpG‐ASO‐Pt‐Loaded Macrophages (CAP@ M) for Synergistic Chemo‐/Gene‐/Immuno‐Therapy | |
| Ma et al. | Bioinspired spatiotemporal management toward RNA therapies | |
| Porello et al. | Advancing nucleic acid delivery through cationic polymer design: non-cationic building blocks from the toolbox | |
| Kubisa et al. | Star‐shaped copolymers with PLA–PEG arms and their potential applications as biomedical materials | |
| Abrishami et al. | Enhanced theranostic efficacy of epirubicin-loaded SPION@ MSN through co-delivery of an anti-miR-21-expressing plasmid and ZIF-8 hybridization to target colon adenocarcinoma | |
| Choi et al. | Cumulative directional calcium gluing between phosphate and silicate: A facile, robust and biocompatible strategy for siRNA delivery by amine-free non-positive vector | |
| Karati et al. | A comprehensive review on targeted cancer therapy: new face of treatment approach | |
| Fewell et al. | Treatment of disseminated ovarian cancer using nonviral interleukin‐12 gene therapy delivered intraperitoneally | |
| Breusa et al. | Localized chemotherapy approaches and advanced drug delivery strategies: a step forward in the treatment of peritoneal carcinomatosis from ovarian cancer | |
| Laomeephol et al. | Potential roles of hyaluronic acid in in vivo CAR T cell reprogramming for cancer immunotherapy |